EP300/CBP are histone acetyltransferases recruited onto chromatin by oncogenic transcription factors and control the transcriptional program via their activity in enhancer areas. Nicosia et al. offer new promise in targeting EP300/CBP using the small-molecule inhibitor CSS1477 in patients with blood tumours and no other therapeutic options.

This year was a significant period for our Institute as we made the long-anticipated return to the Paterson Building, our brand-new research facility on the Christie NHS Foundation Trust site. Find out how our staff continued to excel in all aspects of Institute life and reconnected with the wider scientific community within the Manchester Cancer Research Centre.